Publications

1. Kriseman, T.,: Rubella Myocarditis in a 9 year old patient. Clin. Ped. 23:240 241, 1984.
2. Rosenbloom, A., Kriseman, T.: Preference of youth between two home glucose monitoring systems (Chemstrip/Visidex). (Letter) Diabetes Care (6):616 617, 1983.
3. Kriseman, T., Underwood, D., Kadowitz, P.: Analysis of Airway Responses to A23187 in the cat. J. Pharmacol. Exp. Therapeutics. 239(2):395 399, 1986.
4. Kriseman, T., Underwood, D., McNamara D, Kadowitz, P.: Inhibition of A23187 induced bronchoconstriction by dazoxiben, a thromboxane synthesis inhibitor. Am. J. Med. Sci. 293(2):349-353, 1987.
5. Kriseman, T., Underwood, D., Kadowitz, P.: Inhibition of E. Coli endotoxin induced bronchoconstriction by SQ 29,548, a thromboxane receptor antagonist. Am Rev Resp Dis 133(4): A282,1986.
6. Kriseman, T., Underwood, D., Kadowitz, P.: Inhibition of A23187 induced bronchoconstriction by dazoxiben, a thromboxane synthesis inhibitor. Clin Res 34:262A, l986. Young Investigator award.
7. Underwood, D., Kriseman, T., McNamara D.B., Kadowitz, P.: Differential effects of thromboxane synthesis and receptor blockade on airway responses to arachidonic acid, PGH2,and the calcium ionophore A23187. Fed Proceedings 45:(13) 2937 A, 1986.
8. Underwood, D., Kriseman, T., Hyman, A., Kadowitz, P.: The effect of SQ 29,548 and meclofenamate on PAF induced bronchoconstriction in the cat. Circulation 72:A, 1986.
9. Underwood, D., Kriseman, T., McNamara, D., Hyman, A., Kadowitz,P.: Blockade of thromboxane responses in the airway of the cat by SQ 29,548. J Appl Physiol 62:2193-2200,1987.
10. Underwood, D., Kriseman, T., Kadowitz, P.: The effect of SQ 29,548 on endotoxin induced bronchoconstriction in the cat. Shock Conference Abstr.
11. Kriseman, T., Sherman, J., Nelson H.: Oximetry during sleep in neonates receiving supplemental oxygen. Am Rev Respir Dis 137:16A,1988.
12. Kriseman, T., Sherman, J., Nelson H.: Breath activation of metered dose inhalers. Am Rev Respir Dis 137:499A,1988.
13. Cawkwell, G., Lacson, A., Kriseman,T.:Pathological case of the Month. Arch Pediatr Adolesc Med 155:853-854,2001.

NIH Grants

1. HL07053-01 Thromboxane A1 and A2 - Airway responses in the cat. Tulane University School of Medicine, New Orleans, LA. Principal Investigator 1984 - 1986.
2. 6119136LO Sulfur hexafluoride washout for measurement of lung volumes in neonates. Principal investigator. 1987-1988.
3. Gulf Coast Lung Association. 6119138LO Oximetry during sleep in neonates receiving supplemental oxygen. Principal investigator. 1987-1988.
4. Gulf Coast Lung Association. Ultrasound correlation of lung volume with post - natal determination of functional residual capacity. Principal investigator. 1989-1990.

Genentech Grants

1. A Multicenter, Open Label Treatment Protocol to Provide Aerosolized rhDNase Therapy to Patients with Cystic Fibrosis. (Z0507g-A2) Principal Investigator. (1992-1994)
2. A Multicenter, Epidemiologic Protocol to Evaluate Pulmonary Function and the Rate of Respiratory Tract Infections in Patients with Cystic Fibrosis. (Z0525n) Principal Investigator. (1992-1994)
3. A Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Aerosolized rhDNase Therapy in Patients with Cystic Fibrosis Who Have Advanced Lung Disease. (Z0554g) Principal Investigator. (1993-1994)
4. Epidemiologic Study of Cystic Fibrosis: A Multicenter, Longitudinal Follow-up Study of Patients with Cystic Fibrosis for Monitoring Pulmonary Function, Pulmonary Exacerbations, and the Safety of Long-Term Treatment with PulmozymeR (dornase alfa) (Z0595n) Principal Investigator. (1994-ongoing)
5. A Phase III Multi-center, double blind, placebo controlled parallel study, to evaluate the safety and efficacy of aerosolized recombinant human DNase-1 (rhDNase) in patients with Cystic Fibrosis. (Z0343) Principal Investigator.(1992-1993)
6. A Phase IV, Multicenter, Study to Monitor the Long-Term Safety and Efficacy of PulmozymeR (dornase alfa)in Cystic Fibrosis Patients Who Participated in a Phase III Study. (Z0620) Principal Investigator. (1994-1996)
7. A Multicenter, International, Randomized, Placebo controlled, Double blind Study to Determine the Effect of Pulmozyme® on Pulmonary Function over 96 Weeks in Subjects with Cystic Fibrosis Aged 6-10 years (Z0713)Principal Investigator. (1997-1999)
8. A Double-Blind, Randomized, Placebo-Controlled Surveillance Study Of Asthma Event Outcomes In Subjects Receiving Either Usual Pharmacotherapy Of Asthma Or Usual Pharmacotherapy Plus Salmeterol 42 mcg (2 Puffs) Twice Daily (Protocol SLGA5011) Principal Investigator (2000-2001)
9. A Multicenter, Randomized, Controlled, Open-label Study To Evaluate The Safety Of Xolairtm In Moderate To Severe, Persistent Asthma Subjects Already Treated With Other Therapies (ALTO) Principal Investigator (2001-present)
10. An Observational Study Of The Epidemiology and Natural History of Asthma:Outcomes and Treatment Regimens (TENOR)Principal Investigator(2001-present)
11. An Open-label Extension Study Of XolairT(Omalizumab)In Moderate To Severe,persistent Asthma Subjects Who Completed Study Q2143g(ALTO)Principal Investigator(2001-present)
12. A Randomized, Double blind, Placebo controlled Study To Investigate The Efficacy And Safety Of 24 Weeks Of Oral Treatment With BIIL 284 BS In Adult (75 Mg, 150 Mg) And Pediatric (75 Mg) Cystic Fibrosis Patients